A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 422, Issue 2, 1998, Pages 271-277

  Parashar, Kamana ^a   Sobti, R C ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

p53; p53 antibody; p53 in oesophageal cancer; p53 protein

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032481090     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00207-3     Document Type: Article

References (46)

1. Crespi M., Grassi A., Amiri G., Munoz N., Aramesh B., Mojtabi A., Casale V. Oesophageal lesions in Northern Iran: a premalignant condition? Lancet. 2:1979;217.
2. R.S. Cotran, V. Kumar, S.L. Robbins, in: Robbins Pathological Basis of Disease, 1989, 835-838.
3. N. Munoz, M. Crespi, in: P. Sherlock, B.C. Morson, L. Barbara, U. Veronisi (Eds.), Precancerous Lesion of the Gastrointestinal Tract, Raven Press, New York, 1983, 53.
4. El Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., Wiman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kizler K.W., Vogelstein B. Waf 1/Cip 1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
5. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
6. Lane D.P. p53, guardian of the genome. Nature (London). 358:1992;15-16.
7. Smith M.L., Chen I.-T., Zhan Q., Bae I., Chen C.-Y., Gilmer T.M., Kastan M.B., O'Connor P.M., Fornace A.J. Interaction of the p53-regulated protein Gadd 45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1380.
8. Cross S.W., Sanche C.A., Morgan C.A., Schmike M.K., Hamel S., Idzerda R.L., Haskind W.H., Reid B.J. A p53 dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
9. Powell S.N., DeFrank J.S., Connell P., Eogan M., Preffer F., Dombrowski D., Tang W., Friend S. Differential sensitivity of p53(-) and p53(+) cells to caffeine induced radiosensitization and override of G2 delay. Cancer Res. 55:1995;1643-1648.
10. Russell K.J., Wiens L.W., Demers W.G., Galloway D.A., Plon S.E., Groudine M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res. 55:1995;1639-1642.
11. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
12. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
13. Bartek J., Iggo R., Gannon J., Lane D.P. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer. Oncogene. 5:1990;893-899.
14. Davidoff A.M., Humphrey P.A., Iglehart J.D., Marks J.R. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5006-5010.
15. Iggo R., Gatter K., Bartek J., Lane D., Harris A.L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 335:1990;675-679.
16. Mulligan L.M., Matlashewski G.J., Scrable H.J., Cavena W.S. Mechanisms of p53 loss in human sarcomas. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5863-5867.
17. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Sevilee P., Glover T., Collino F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature (London). 342:1989;705-708.
18. Rodrigues E., Rao P.H., Ladanyi M., Altorki N., Albino A.P., Kelsen D.P., Jhanwar S.C., Chaganti R.S.K. 11p13-15 is a specific region of chromosomal rearrangement in gastric and oesophageal adenocarcinomas. Cancer Res. 50:1990;6410-6416.
19. Shindoh M., Chiba I., Yasuda M., Saito T., Funaoka K., Kohgo T., Amesmiya A., Sawada Y., Fujinaga K. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer. 76:1995;1513-1521.
20. Parada L.F., Land H., Weinberg R.A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature. 312:1984;649-651.
21. Cesarman E., Inghirami G., Chadburn A., Knowles D.M. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am. J. Pathol. 143:1993;845-856.
22. Hino N., Kondo K., Miyoshi T., Uyama T., Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br. J. Cancer. 76:1997;1361-1366.
23. Matsushima A.Y., Cesarman E., Chadburn A., Knowles D.M. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am. J. Pathol. 144:1994;573-584.
24. Villuendas R., Puis M.A., Algara P., Sanchez B.M., Sanchez V.L., Martinez J.C., Orradre J.L., Garcia P., Lopez C., Martinez P. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood. 82:1993;3151-3156.
25. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer. 30:1982;403-408.
26. Bourhis J., Lubin R., Roche B., Koscielny S., Bosq J., Dubois I., Talbot M., Marandas P., Schwaab G., Wibault P., Luboinski B., Eschwege F., Soussi F. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88:1996;1128-1233.
27. Laberecque S., Naor N., Thomson D., Matlashewsky G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res. 53:1993;3468-3471.
28. Peyray J.-P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 345:1995;621-622.
29. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Souski T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:1992;6380-6384.
30. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:1992;4168-4174.
31. Angelopoulou K., Diamandis E.P., Sutherland D.J., Kellen J.A., Bunting P.S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer. 58:1994;480-487.
32. Vojtesek B., Fisher C.J., Barnes D.M., Lane D.P. Comparison between p53 staining in tissue sections and p53 protein levels measured by an ELISA technique. Br. J. Cancer. 67:1993;1254-1258.
33. Levesque M.A., Katsaros D., Yu H., Zola P., Sismondi P., Giardina G., Diamandis E.P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338.
34. Lehtinen T., Aine R., Lehtinen P.K., Hakala T., Lehtinen M. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma. Acta Oncologica. 32:1993;779-781.
35. Levesque M.A., Costa M.D., Diamandis E.P. p53 protein is absent from the serum of patients with lung cancer. Br. J. Cancer. 74:1996;1434-1440.
36. Luo J.-C., Zehak R., Anttila S., Ridanpaa M., Husgaf-vel-Pursiainen K., Vainio H., Carney W., DeVivo I., Milling C., Brandt-Rauf P. Detection of serum p53 protein in lung cancer patients. J. Occup. Med. 36:1994;155-160.
37. Partenen R., Koskinen H., Oksa P., Hemminki K., Carney W., Smith S., Brandt-Rauf P. Serum oncoproteins in Asbestosis patients. Clin. Chem. 41:1995;1844-1847.
38. Schlichtholz B., Tredaniel J., Lubin R., Zalcman G., Hirsch A., Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer. 69:1994;809-816.
39. Banks L., Matlashewski G., Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. J. Biochem. 159:1986;529-534.
40. Caron de Fromental C., May-Levin F., Mourusse H., Lemerle J., Chandrasekaran K., May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer. 39:1987;185-189.
41. Davidoff A.M., Iglehart J.D., Marks J.R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. U.S.A. 89:1992;3439-3442.
42. Kurvinen K., Syrjanen K., Syrjanen S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus associated cervical lesions. J. Clin. Oncol. 14:1996;2120-2130.
43. Baas I.O., Mulder J.W.R., Offerhaus J.A., Vogelstein B., Hamilton S.R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 172:1994;5-12.
44. Barnes D.M., Handby A.M., Gillett C.E. Abnormal expression of wild type p53 protein in normal cell of cancer family patient. Lancent. 340:1992;259-263.
45. Lane D.P., Crawford L.V. Tantigen is bound to a host protein in SV40 transformed cells. Nature (London). 278:1979;261-263.
46. Bennett W.P., Colby T.V., Travis W.D., Borkowski A., Jones R.T., Lane D.P., Metacalf R.A., Samet J.M., Takeshima Y., Gu J.R., Vahankangas K.H., Soini Y., Paabko P., Welsh J.A., Trump B.F., Harris C.C. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 53:1993;4817-4822.